Yoshito Komatsu
Hokkaido University
338 Papers
1.1K Citations
Yoshito Komatsu is an academic researcher from Hokkaido University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 278 publications.
Chat about Author
Papers
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial.
Robert J. Mayer,Atsushi Ohtsu,Takayuki Yoshino,Alfredo Falcone,Rocio Garcia-Carbonero,Guillem Argiles,Azzurra Damiani,Marc Peeters,Lukas Makris,Alberto Zaniboni,Yasuhiro Shimada,Kentaro Yamazaki,Yoshito Komatsu,Howard S. Hochster,Heinz-Josef Lenz,Ben Tran,Robert Winkler,Paul Bebeau,M. Wahba,Eric Van Cutsem +19 more
TL;DR: TAS-102 contains an antineoplastic nucleoside, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio of 1:0.5.
3
Dose escalation and expansion cohort study for DS-8895a in patients with advanced solid tumors.
Taroh Satoh,Kohei Shitara,Satoru Iwasa,Kensei Yamaguchi,Kei Muro,Yoshito Komatsu,Tomohiro Nishina,Taito Esaki,Jun Hasegawa,Yasuyuki Kakurai,Emi Kamiyama,Tomoko Nakata,Kota Nakamura,Ichinosuke Hyodo +13 more
TL;DR: DS-8895a was safe and well tolerated up to 20 mg/kg and the PK of DS-88 95a was dose-dependent as expected, and biomarkers had no apparent relationship to best overall response.
3
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
Hiroki Osumi,Eiji Shinozaki,M. Nakamura,Taito Esaki,Hisateru Yasui,Hiroya Taniguchi,Hironaga Satake,Yu Sunakawa,Yoshito Komatsu,Yoshinori Kagawa,Tadamichi Denda,Manabu Shiozawa,Taroh Satoh,Tomohiro Nishina,Masahiro Goto,Naoki Takahashi,Takeshi Kato,Hideaki Bando,Kensei Yamaguchi,Takayuki Yoshino +19 more
TL;DR: In this paper , the authors defined Neo RAS WT as no RAS MT ( KRAS or NRAS) detected in plasma and was assessed in the overall cohort (Cohort A) and in the subgroup with at least one somatic alteration detected in placenta to exclude those with insufficient tumor DNA shedding.
3
A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).
Yuji Miyamoto,Satoshi Yuki,Mototsugu Shimokawa,Hiroaki Tanioka,Akihito Tsuji,Masako Asayama,Takeshi Shiraishi,Masahito Kotaka,Akitaka Makiyama,Yoshito Komatsu,Satohiro Masuda,Takuhiro Yamaguchi,Hiroshi Saeki,Eiji Oki,Yasunori Emi,Hideo Baba,Yoshihiko Maehara +16 more
TL;DR: KSCC1402/HGCSG1402 is a phase II, randomized, double-blind, placebo-controlled study evaluating the prophylactic effects of oral dex on REG-related fatigue and malaise for pts with mCRC.
3
Metachronous gastric cancer following complete remission of gastric MALT lymphoma
Shouko Ono,Mototsugu Kato,Kikuko Takagi,Jyunichi Kodaira,Kanako Kubota,Yoshihiro Matsuno,Yoshito Komatsu,Masahiro Asaka +7 more
TL;DR: Three cases have maintained complete remission of the gastric MALTymphoma but developed intestinal-type gastric cancer in the same areas where the MALT lymphoma had been eradicated; however, metachronous gastric cancers developed during long-term follow-up.
3